Pediatr. praxi. 2009;10(1):31-34
HPV vaccination update - new reccommendation
- Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
A vaccination against human papillomaviruses is primary prevention for malignant lesions joined with HPV 16 and 18 especially for
cervical cancer. With the addition of cross protection against other HPV types it could cover more than 80% of cervical cancers. The usage
of quadrivalent vaccine have added value in possibility to safe also against genital warts and other lesions induced by HPV 6 and
11. The best results are reached by vaccination of HPV-naive persons which have not come into contact with this most frequent sexually
transmitted infection. Vaccination is useful also in older women.
Keywords: HPV, vaccination, cervical cancer, genital warts.
Published: March 1, 2009 Show citation
References
- Bosch FX, Castellsague X, Sanjosé S. HPV and cervical cancer: screening or vaccination. Br J of Cancer 2008; 98: 15-21.
Go to original source... 
Go to PubMed... - Fait T, Vrablík M, Češka R, a kol. Preventivní medicína. Praha: Maxdorf Jessenius 2008: 554 s.
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against HPV to prevent anogenital disease (FUTURE I). N Engl J Med 2007; 356(19): 1928-1943. Go to original source... Go to PubMed...
- Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of quadrivalent prophylactic HPV (type 6, 11, 16, 18) L1 viruslike-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007; 369: 1693-1702. Go to original source... Go to PubMed...
- Crosbie EJ, Kitchener HC. Cervarix - a bivalent L1 VLP vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther 2007; 7, 3: 391-395. Go to original source... Go to PubMed...
- Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 LV VLP vaccine formulated with the MLP/aluminium salt combination (AS04) comapred to aluminium salt only. Vaccine 2006; 24: 5937-5949. Go to original source... Go to PubMed...
- Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of HPV VLP type 16 prophylactic vaccine. Vaccine 2007; 25: 4324-4333. Go to original source... Go to PubMed...
- Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent HPV type 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Brit J Cancer 2006; 95: 1459-1466. Go to original source... Go to PubMed...
- Paavonen J, Jenkins D, Bosh FX, et al. Efficacy of a prophylactis adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women. Lancet 2007; 369: 2161-2170. Go to original source... Go to PubMed...
- Villa LL, Ault KA, Giulian AR. Immunologic response following administration of a vaccine targeting HPV types 6, 11, 16 a 18. Vaccine 2006; 7: 557-583.
- Harper M, Paavonen J. Age for HPV vaccination. Vaccine 2008; 265: A7-A11. Go to original source... Go to PubMed...
- Future II Study Group. Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N Engl J Med 2007; 356, 19: 1915-1927. Go to original source... Go to PubMed...
- Wright TC, Bosch FX. Is viral status needed before vaccination? Vaccine 2008; 265: A12-A15. Go to original source... Go to PubMed...
- Franco EL, Cucick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 265: A16-A23. Go to original source... Go to PubMed...
- Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for HPV Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin 2007; 57: 7-28. Go to original source... Go to PubMed...